ArticleGeneral thoracic and cardiovascular surgery2021
18F-FDG-PET/CT predicts grade of malignancy and invasive potential of thymic epithelial tumors.
Article in General thoracic and cardiovascular surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Non-mucinous, enteric-type thymic adenocarcinoma: genetic analysis of a case.General thoracic and cardiovascular surgery cases · 2026Article
- Clinical significance of positron emission tomography-computed tomography in the classification of thymic tumors.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- The Role of [Molecular diagnosis & therapy · 2025Article
- Practical value of fluorodeoxyglucose positron emission tomography in treatment strategies for thymic epithelial tumors: implications for more specific use in routine clinical practice.Mediastinum (Hong Kong, China) · 2025Review
- Machine learning models from computed tomography to diagnose thymic epithelial tumors requiring combined resection.Journal of thoracic disease · 2024Article
- Avoiding misdiagnosis of multilocular thymic cysts as malignant tumors on computer tomography.World journal of clinical cases · 2024Article
- The clinical signification and application value of [Endocrine · 2024Article
- Prognosis of Concurrent Versus Sequential Chemo-Radiotherapy Induction Followed by Surgical Resection in Patients with Advanced Thymic Epithelial Tumors: A Retrospective Study.Annals of surgical oncology · 2023Article
- Superiority of [European journal of nuclear medicine and molecular imaging · 2023Article
- Is PET/CT Able to Predict Histology in Thymic Epithelial Tumours? A Narrative Review.Diagnostics (Basel, Switzerland) · 2022Review
- Multiparameter diagnostic model based onBMC cancer · 2022Article
- How can the rate of nontherapeutic thymectomy be reduced?Interactive cardiovascular and thoracic surgery · 2022Article
- Can the Ratio SUVmax of the Lesion/SUVmax of Mediastinal Tissues Guide the Choice of Surgical Access for the Resection of Thymic Epithelial Tumors?Frontiers in surgery · 2022Article
- Current Roles of PET/CT in Thymic Epithelial Tumours: Which Evidences and Which Prospects? A Pictorial Review.Cancers · 2021Review
- An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the ability of fluorine-18-fluorodeoxyglucose positron emission tomography coupled with computed tomography (18F-FDG-PET/CT) to predict the WHO malignancy grade, initial staging, and invasive potential of thymic epithelial tumors.
methodsWe retrospectively reviewed the medical records of 56 patients with thymic epithelial tumors who were evaluated by PET/CT before surgery and underwent surgical resection. We analyzed the relationship of the maximum standardized uptake value (SUVmax) with the WHO histological classification, tumor invasion, TNM classification, and the Masaoka-Koga classification.
resultsThere were differences of SUVmax of the FDG-PET between thymic carcinoma (9.09 ± 3.34) and thymoma (4.86 ± 2.45; p < 0.01), thymic carcinoma (9.09 ± 3.34) and high-grade thymoma (6.01 ± 2.78; p < 0.01), and high-grade thymoma (6.01 ± 2.78) and low-grade thymoma (4.06 ± 1.86; p < 0.01). The cut-off value for the SUVmax was 7.40 and 5.40, and the sensitivity/specificity for predicting the histologic subtype of each group was 0.72/0.79 and 0.61/0.85, respectively. According to T classification, SUVmax was significantly higher in T3 (8.31 ± 2.57) than in T1a (4.45 ± 2.06; p < 0.01). Regarding Masaoka-Koga classification and WHO histological classification, a significantly higher SUVmax was detected in patients with stage III and IV disease than in those with stage I and II diseases (p < 0.01). The cut-off value for SUVmax was 5.40 in Masaoka-Koga stage and 5.60 in the WHO classification; the sensitivity/specificity for predicting the histologic subtype was 0.85/0.80 and 0.89/0.78, respectively.
conclusionsFDG-PET is a useful tool to predict aggressiveness of thymic epithelial tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.